Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,538
datasets available to search
ShareScore release 0.9.0
Dataset results
2,538 results for “follow-up”
Avascular Necrosis (AVN) Long-Term Follow-up
ClinicalTrials.gov study NCT00833430. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Use of Capsaicin Challenge for Diagnosis, Monitoring and Follow-up of Chronic Cough.
ClinicalTrials.gov study NCT01807832. IPD Sharing: Not stated. Countries: 0. Publications: 0.
IDH1/2 Mutational Analysis in AML Patients: Diagnosis and Follow-up
ClinicalTrials.gov study NCT04242849. IPD Sharing: NO. Countries: 0. Publications: 0.
Impact of Gene Dosage on Gene Expression, Biological Processes and Survival in Cervical Cancer: a Genome-Wide Follow-Up Study
GEO Series GSE52904. Homo sapiens. 199 samples. Type: Genome variation profiling by SNP array; Genome variation profiling by genome tiling array; Expression profiling by array.
Down-regulation of Interferon signature in systemic lupus erythematosus patients by active immunization with Interferon alpha-Kinoid extended follow-up
GEO Series GSE72754. Homo sapiens. 52 samples. Type: Expression profiling by array.
Chandra Serendipitous Extragalactic X-Ray Source ID (SEXSI) Optical Follow-Up
The Serendipitous Extragalactic X-ray Source Identification (SEXSI) Program is designed to expand significantly the sample of identified extragalactic hard X-ray sources at intermediate fluxes, 10<sup>-15</sup> ergs/cm<sup>2</sup>/s < 2-10 keV Flux <~ 10<sup>-13</sup> ergs/cm<sup>2</sup>/s. SEXSI, which includes sources derived from more than 2 square degrees of Chandra images, provides the largest hard X-ray-selected sample yet studied, offering an essential complement to the Chandra Deep Fields (total area of 0.2 square degrees). In Eckart et al. (2005, Paper II) R-band optical imaging of the SEXSI fields from the Palomar P60 and P200, the MDM 2.4m and 1.3m, and the Keck I telescopes is described. The authors have identified counterparts or derived flux limits for nearly 1000 hard X-ray sources. Using the optical images, they have derived accurate source positions. They have investigated correlations between optical and X-ray flux, and optical flux and X-ray hardness ratio. They have also studied the density of optical sources surrounding X-ray counterparts, as well as the properties of optically faint, hard X-ray sources. In Eckart et al. (2006, Paper III) optical spectra of 477 counterparts are presented. These spectra reach to R-band magnitudes of <~24 and have produced identifications and redshifts for 438 hard X-ray sources. Typical completeness levels in the 27 Chandra fields studied are 40-70%. The vast majority of the 2-10 keV selected sample are AGNs with redshifts between 0.1 and 3; the highest redshift source lies at z = 4.33. This table which combines data presented in Eckart et al. (2005, 2006) has links to the list of SEXSI X-ray sources (the HEASARC Browse table CHANSEXSI: see Paper I = Harrison et al. 2003, ApJ, 596, 944). This table was originally created by the HEASARC in June 2005 based on the CDS version of Table 3 from Eckart et al. (2005: CDS table J/ApJS/156/35/table3.dat). It was updated in August 2006 to include information from Table 2 of Eckart et al. (2006: the electronic version available at the electronic ApJ web site). This is a service provided by NASA HEASARC .
Treatment Naïve and Follow-Up Pediatric Ulcerative Colitis Rectal Gene Expression
GEO Series GSE150961. Homo sapiens. 418 samples. Type: Expression profiling by high throughput sequencing.
mRNA-seq data for KMT2D HNSCC (follow-up)
GEO Series GSE185536. Homo sapiens. 6 samples. Type: Expression profiling by high throughput sequencing.
Gene expression analisys of GD2+ cells from metastatic NB, unselected bone marrow from metastatic NB, primary tumors from stage 4 NB (alive and dead at 5 years of follow-up) and primary tumor from loc
GEO Series GSE112447. Homo sapiens. 57 samples. Type: Expression profiling by array.
Dataset related to article: "Time Course of Autonomic Symptoms in Postural Orthostatic Tachycardia Syndrome (POTS) Patients: Two-Year Follow-Up Results
<p>This record contains data related to article "Time Course of Autonomic Symptoms in Postural Orthostatic Tachycardia Syndrome (POTS) Patients: Two-Year Follow-Up Results"</p> <p>Postural orthostatic tachycardia syndrome (POTS) is a multifactorial condition capable of<br> chronically reducing the quality of life and the work ability of patients. The study aim was to assess<br> the burden of autonomic symptoms in a cohort of POTS patients over 2 years. Patients’ clinical profiles<br> were assessed by the 31-item Composite Autonomic Symptom Score questionnaire (COMPASS 31)<br> and a visual analog scale (VAS). One-way ANOVA for repeated measures followed by Dunnett’s<br> post-hoc test were used to compare symptoms at baseline and at 1 and 2 years. Out of 42 enrolled<br> patients, 25 had a 1-year follow-up and 12 had a 2-year follow-up. At baseline, the reported burden<br> of autonomic symptoms was high (overall COMPASS 31 = 49.9 14.3 /100). Main complaints were<br> related to orthostatic intolerance according to both COMPASS 31 and VAS. Fourteen patients were<br> rendered inactive because of symptoms. At 1-year follow-up, a statistically significant improvement<br> in pupillomotor function and overall score was detected by the COMPASS 31. These findings were<br> confirmed at 2 years, together with a significant reduction in quality of life impairment, assessed<br> by VAS. However, these improvements did not change patients’ occupational status. Awareness of<br> POTS diagnosis, patient monitoring, and tailored therapies can help to improve patients’ condition.</p>
Dataset related to article "Impact of delay in follow-up due to COVID-19 pandemic on skin cancer progression: a real-life experience from an Italian hub hospital "
<p>This record contains data related to article "Impact of delay in follow-up due to COVID-19 pandemic on skin cancer progression: a real-life experience from an Italian hub hospital "</p> <p>Abstract</p> <p><strong>Background: </strong> The COVID-19 pandemic required the setting of a national lockdown in Italy from March 9, 2020, until May 18, 2020; therefore, most of the non-COVID-19 activities were postponed. As a consequence, many follow-up visits in patients with previously excised skin cancers were delayed. The aim of this retrospective real-life case-control study is demonstrating that delay in follow-up led to an increased incidence of advanced melanoma and keratinocyte cancers on the total of surgically excised skin cancers.</p> <p><strong>Methods: </strong> The incidence of excised advanced melanoma and keratinocyte cancers in our dermato-surgery division in the period May 18 to November 18, 2020, was compared to the same time span of 2019. All data were collected from the electronic database of our department. Odds ratio with 95% confidence interval was used to assess the risk of excised advanced skin cancers in 2020 compared to 2019.</p> <p><strong>Results: </strong> From May to November 2019, we performed 265 surgical excisions, while during the pandemic in 2020, we completed 280 surgeries. The number of advanced skin cancers excised between May 18 and November 18, 2020, was significantly higher compared with the same period in 2019 (54 vs. 22, OR: 2.64; 95% CI: 1.56-4.47; P = 0.0003). Significant differences were also observed regarding the number of surgically removed advanced BCCs (OR 2.15; 95% CI 1.14-4.07; P = 0.0187) and advanced SCCs (OR 4.60; 95% CI 1.31-16.18; P = 0.0175).</p> <p><strong>Conclusion: </strong> These results confirm that delay in follow-up and, consequently, postponed surgical excisions are related to an increased incidence of advanced skin tumors, resulting in poorer prognosis lifelong. Follow-up visits should be carried on even during COVID-19 pandemic, avoiding significant delays as much as possible. </p>
Comparison of multiple software in the identification of risky drug-drug interactions in pharmacotherapeutic follow-up through telepharmacy
<p>The data that support the findings of this study are available from the corresponding author upon reasonable request. Please contact gdelgadop@unmsm.edu.pe to request access to the data.</p>
Dataset related to article "Long-Term Follow-Up of Patients with Metastatic Epidural Spinal Cord Compression from Solid Tumors Submitted for Surgery Followed by Radiation Therapy"
<p>This record contains raw data related to article "Long-Term Follow-Up of Patients with Metastatic Epidural Spinal Cord Compression from Solid Tumors Submitted for Surgery Followed by Radiation Therapy"</p> <p>OBJECTIVE:</p> <p>To evaluate the outcome of patients with epidural spinal cord compression from different solid tumors treated with a combined approach, surgery plus radiotherapy (RT), with a follow-up longer than 10 years.</p> <p>METHODS:</p> <p>Ninety-seven patients treated between 2002 and 2009 were included. Surgical treatment was performed in patients with good performance status, limited metastatic disease, life expectancy longer than 3 months, and progressive neurologic deficit and/or intractable pain. RT was performed delivering a median total dose of 30 Gy in 10 fractions. Clinical outcome was evaluated using the modified visual analog scale for pain, the Frankel scale for neurologic deficit, and magnetic resonance imaging before treatment, after treatment, and every 3 months thereafter.</p> <p>RESULTS:</p> <p>Palliative decompression was performed in 27% of patients, tumor curettage (debulking) was performed in 51%, and total vertebrectomy was performed in 22%, followed by RT in 78% of cases. Pain remission was obtained in 98% of patients, and recovery of neurologic function was obtained in 51%. The median follow-up time was 135 months (range, 96-209 months). The 5- and 10-year local control rates were 82.8% and 82.8%, respectively. The median and 5- and 10-year progression-free survival rates were 12 months, 16.9%, and 11.3%, respectively; the median and 5- and 10-year overall survival rates were 18 months, 21.3%, and 12%, respectively. On univariate and multivariate analysis, factors recorded as conditioning survival were the performance status and the presence of other metastases at the time of vertebral treatment (P < 0.01).</p> <p>CONCLUSIONS:</p> <p>Our update confirmed that surgery plus RT is a safe and feasible treatment with limited morbidity. In selected patients with favorable prognostic factors, the combined treatment may significantly impact on survival.</p>
Dataset related to article "Phase II trial on SBRT for unresectable liver metastases long-term outcome and prognostic factors of survival after 5 years of follow-up"
<p>This record contains raw data related to article "Phase II trial on SBRT for unresectable liver metastases long-term outcome and prognostic factors of survival after 5 years of follow-up"</p> <p>BACKGROUND:</p> <p>The aim of this study was to evaluate long-term efficacy and survival prognostic factors of stereotactic body radiation therapy (SBRT) for un-resectable liver metastases in patients enrolled in a prospective phase II trial.</p> <p>METHODS AND MATERIALS:</p> <p>5-year local control (LC), overall survival (OS), progression free survival (PFS) and toxicity rates were analyzed in patients with un-resectable liver metastases enrolled in a Phase II Trial on liver SBRT, with a prescription dose of 75Gy in 3 consecutive fractions.</p> <p>RESULTS:</p> <p>A total of 61 patients with 76 lesions were enrolled, with a median follow-up time of 6.1 years. One, three and 5 year LC rates were 94 ± 3.1%, 78.0 ± 5.9% and 78.0 ± 5.9%, without reaching the median LC time. Median OS was 27.6 months and the survival rates were 85.2 ± 4.5%, 31.1 ± 5.9% and 18.0 ± 4.9% at 1, 3 and 5-year after SBRT, respectively. Univariate analysis showed that favorable primary site (colorectal, breast and gynecological) of metastases (p = 0.001) improved survival. Toxicity was moderate. One patient experienced G3 late chest wall pain, which resolved within 1 year from SBRT. No cases of Radiation Induced Liver Disease (RILD) were detected.</p> <p>CONCLUSIONS:</p> <p>Long-term results of this Phase II study suggest the efficacy and safety of SBRT for un-resectable liver metastases after 5-year of follow up. Selection of cases with positive prognostic factors may improve long-term survival of these oligo-metastastic patients and may confirm the role of SBRT as an effective alternative local therapy for liver metastases.</p>
Long-term knee health in adults with a history of adolescent Osgood-Schlatter: A cross-sectional follow-up on a national cohort of patients from secondary care in Denmark 1977-2020
Open the record for dataset details and reuse information.
Dataset related to article "Long term follow-up after balloon expandable covered stents implantation for management of transcatheter aortic valve replacement related vascular access complications"
<p>This record contains raw data related to article “Long term follow-up after balloon expandable covered stents implantation for management of transcatheter aortic valve replacement related vascular access complications"</p> <p>Abstract</p> <p><strong>Objectives: </strong> To report the experience of a high-volume center with balloon-expandable (BE) stents implantation to manage vascular complications after transcatheter aortic valve replacement (TAVR).</p> <p><strong>Background: </strong> Despite increased operator experience and better devices, vascular complications after TAVR are still a major issue and covered stent implantation is often required.</p> <p><strong>Methods: </strong> We retrospectively collected baseline and procedural data about 78 consecutive patients who underwent BE stent implantation to manage a vascular complication after transfemoral TAVR. Primary endpoints were technical success, incidence of new-onset claudication and need for vascular interventions during long-term follow-up. Secondary endpoints included length of hospitalization, in-hospital and 30-day mortality, and major postoperative complications.</p> <p><strong>Results: </strong> BE stents implantation to manage vascular complications after TAVR was successfully performed in 96.2% of the cases, with bailout surgery required in two cases. One patient suffered in-hospital death. Predischarge Doppler Ultrasound revealed no cases of in-stent occlusion or fracture. At a median follow-up of 429 days (interquartile range, 89-994 days), no cases of symptomatic leg ischemia were reported and only one patient experienced new-onset claudication.</p> <p><strong>Conclusions: </strong> Our experience showed good periprocedural and long-term results of BE covered stent implantation to manage vascular complication after TAVR. Their great radial outward force may guarantee effective hemostasis without necessarily being associated with stent deformation/fracture resulting in restenosis or further interventions. More research is needed to define the role of BE covered stents in this setting.</p>
Dataset related to article "Why are they not coming back? A single-center follow-up study on oncological women oocyte's storing for fertility preservation"
<p>This record contains data related to article “Why are they not coming back? A single-center follow-up study on oncological women oocyte's storing for fertility preservation"</p> <p> </p> <p>Abstract</p> <p><strong>Introduction: </strong>Oocyte cryopreservation is a valid option for female cancer patients to preserve fertility. The number of patients undergoing fertility preservation (FP) cycles has increased over the past years. Nevertheless, the rates of patients returning to use their cryopreserved material have shown to be considerably low, ranging from 5-8%, but significant data regarding the reasons of such low return rates are scarce.</p> <p><strong>Methods: </strong>This study is a single-center follow-up retrospective study evaluating the return rate of oncological women who underwent FP at a tertiary care Fertility Center and assessing the reasons influencing the patients who did not return. Data about patients who returned to attempt pregnancy were retrieved from internal registries. Non-returned patients were assessed with a standardized phone survey investigating health condition, marital status and family projects, spontaneous conceptions, and the reasons why they had not returned to use their gametes. A univariate analysis between returned and non-returned patients was performed.</p> <p><strong>Results: </strong>Of the 397 patients who received counseling about FP, 171 (43.1%) underwent oocyte cryopreservation between 2001 and 2017. Nine (5%) died, and 17 (10%) were lost at follow-up. A total of 20 patients (11.7%) returned and 125 did not. In the non-returned group, 37 (29.6%) did not have a partner, 10 (8%) had a previous spontaneous conception, and 15 (12%) had recurrent malignancy at the time of follow-up. In the univariate analysis, younger age at freezing (31.8±6.2 vs. 35.2±4.7; p 0.018), lack of a partner (p 0.002), type of cancer (other than breast cancer; p 0.024) were the significant factors in the non-returned group. As for the personal reason for not coming back, patients mainly answered as follows: lack of a partner (29, 23.2%), the desire for spontaneous motherhood (24, 19.2%), previous spontaneous pregnancies after FP procedures (16, 12.8%), and still ongoing hormonal therapy for breast cancer (13, 10.4%). All patients confirmed their will to keep the storage of their oocytes.</p> <p><strong>Discussion: </strong>The impact of a cancer diagnosis on a woman's maternal desire, sentimental status and life priorities should be studied more thoroughly. Studies investigating hormonal therapy suppression in breast cancer patients seeking pregnancy should be encouraged.</p> <p><strong>Clinical trial registration: </strong>https://clinicaltrials.gov, identifier <a href="http://clinicaltrials.gov/show/NCT05223764">NCT05223764</a>.</p> <p> </p>
Datset related to article "Pathways of follow-up care in an Italian center: retrospective study on patients with gliomas II and III"
<p>Database related to the descriptive statistics used to illustrate the characteristics of the sample and to identify the pathways of follow-up care in an Italian center.</p>
Lipoprotein Subfractions and Coronary Heart Disease During 25 Year Follow-up
ClinicalTrials.gov study NCT00005215. IPD Sharing: Not stated. Countries: 0. Publications: 0.
Suppressed Anger, Blood Pressure and Mortality Follow-up
ClinicalTrials.gov study NCT00005458. IPD Sharing: Not stated. Countries: 0. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.